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Abstract
Background: Previous therapy with anthracyclines (ANT) and conditioning regimen followed by hematopoietic
stem cell transplantation (HSCT) represents a high risk for development of cardiotoxicity. The aim of this study was
to assess subclinical myocardial damage after HSCT using echocardiography and cardiac biomarkers - high sensitive
cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and to identify patients at
risk of developing clinical cardiotoxicity.
Patients and methods: Thirty-seven patients who were treated with allogeneic HSCT for hematologic diseases at
median age of 28 years at time of HSCT were studied. Conditioning regimen included either chemotherapy
without total body irradiation (TBI) or combination of chemotherapy with TBI. Twenty-nine (78,3%) patients were
pretreated with ANT therapy. Cardiac biomarkers were serially measured before conditioning regimen and at days
1, 14 and 30 after HSCT. Cardiac systolic and diastolic functions were assessed before conditioning regimen and 1
month after HSCT by echocardiography.
Results: The changes in plasma NT-proBNP and hs-cTnT levels during the 30 days following the HSCT were
statistically significant (P < 0,01 v.s. P < 0,01). Persistent elevations of NT-proBNP and hs-cTnT simultaneously for a
period exceeding 14 days after HSCT were found in 29,7% patients. Serum concentrations of cardiomarkers were
significantly elevated in ANT group compared to non-ANT group. These observations were underscored by the
echocardiographic studies which did reveal significant changes in systolic and diastolic parameters. Five of 37
(13,5%) patients developed clinical manifestation of cardiotoxicity.
Conclusions: Elevations in both cardiac biomarkers were found before clinical signs of cardiotoxicity developed.
Persistent elevations in NT-pro-BNP and hs-cTnT concentrations simultaneously for a period exceeding 14 days
might be used for identification of patients at risk of developing cardiotoxicity and requiring further cardiological
follow up.
Keywords: Hematopoietic stem cell transplantation, Cardiotoxicity, Natriuretic peptides, Cardiac troponins
Background
Stem cells are widely used in the treatment of malignant
and nonmalignant diseases [1]. Advances in allogeneic
hematopoietic stem cell transplantation (HSCT) have
increased survival in hematologic diseases. Among those
who survive the first 2 years, nearly 80% of allogeneic
HSCT recipients are expected to become long-term sur-
v i v o r sa n db y2 0 2 0t h e r em a yb eu pt oh a l fam i l l i o no f
these survivors worldwide [2,3].
However, HSCT survivors are at risk of developing
long-term complications. A fifth of HSCT survivors
develop severe or life-threatening conditions [4]. Cardiac
complications are frequently found life-threatening con-
ditions. When cardiac dysfunction develops, complete
recovery of cardiac function occurs in only 42% of
patients, despite pharmacological therapy [5]. Hence,
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to be validated widely. Measurement of cardiospecific
biomarkers can be a valid diagnostic tool for early iden-
tification, assessment and monitoring of cardiotoxicity.
This approach is minimally invasive, less expensive than
echocardiography and easily repeated.
Cardiac biomarkers are routinely evaluated only in
patients before HSCT with increased cardiac risk [6,7].
Future research should focus on the best timing for
sampling, well-standardized methods for biomarkers
determination and cut-off concentration that gives the
best diagnostic accuracy in terms of sensitivity, specifi-
city and predictive values. We therefore evaluated cardi-
otoxicity using cardiac biomarkers - high sensitive
cardiac troponin T (hs-cTnT) and N-terminal pro-B-
type natriuretic peptide (NT-proBNP) during HSCT in
37 patients in whom echocardiography was performed
before and one month after HSCT.
Patients and methods
Patients
This prospective study involved 37 consecutive patients
with a median age of 28 years (range: 19-58 years) who
underwent an allogeneic hematopoietic stem cell trans-
plantation (HSCT) from June 2009 to February 2011 at
the Transplantation Centre of Hematology Department
at University Hospital Bratislava. There were 24 males
and 13 females. Their diagnosis included acute myeloid
leukemia (AML) in 13 patients, acute lymphoblastic leu-
kemia (ALL) in 14 patients, chronic myeloid leukemia
(CML) in 2 patients, Hodgkin’s lymhoma in one patient,
myelodysplastic syndrome (MDS) in 3 patients, osteo-
myelofibrosis in one patient and severe aplastic anemia
in 3 patients.
Twenty-seven patients were conditioned with myeloa-
blative regimens including cyclophosphamide (CY) 60
mg/kg body weight intravenously on 2 consecutive days
in combination with fractionated total body irradiation
(TBI) 12 Gy in six fractions of 2 Gy over 3 days in 12
patiens or in combination with peroral busulphan 4 mg/
kg body weight daily for 4 days in 15 patients. The
remaining 10 patients were conditioned with nonmye-
loablative regimens (cyclophosphamide, busulphan, flu-
darabine, etoposide, cytosine arabinoside, melphalan,
idarubicin, carmustine or with combination of antithy-
mocyte globulin). Fifteen patients received hematopoie-
tic stem cells from an HLA-matched related donor and
22 patients from an HLA-matched unrelated donor.
Cyclosporine A and short-term methotrexate were
administered for the prophylaxis of graft-versus-host
disease (GVHD). Two patients had arterial hypertension,
2 patients had diabetes mellitus and 14 patients had dys-
lipidemia before transplantation. One patient had a prior
history of a cardiac disease because of leukemic
infiltration of the heart (at the time of diagnosis of acute
leukemia). The cumulative dose of anthracyclines (ANT)
(idarubicin, daunorubicin and mitoxantrone) was calcu-
lated as the equivalent dose of doxorubicin. Twenty-
nine patients were previously treated with ANT (median
250 mg/m
2, range: 100-470). Characteristics of patients
are summarized in Table 1.
The study was approved by the local ethics committee
of University Hospital Bratislava. Written informed con-
sent was obtained from all patients.
Evaluation of cardiac function
Together 148 blood samples were evaluated in 37
patients. Serial measurements of plasma NT-proBNP
and hs-cTnT concentrations were performed the day
before conditioning regimen (baseline), the day after
HSCT (D + 1), 14 days after HSCT (D + 14) and 30
days after HSCT (D + 30) in all patients. Venous blood
samples were obtained from an indwelling catheter in
Table 1 Characteristics of patients
Age at HSCT (median) 19-58 (28 years)
Sex, F/M 13/24
Diagnosis
AML 13
B-ALL 12
T-ALL 2
CML 2
SAA 3
HL 1
OMF 1
MDS 3
Treatment before HSCT
ANT 29
cranial RT (24 Gy) 14
mediastinal RT (24 Gy) 2
Conditioning regimen
BUCY2 15
TBI+CY 12
CY+ATG 1
BCNU+VP-16+ARAC+MEL 1
BU+FLU+CY 3
FLU+CY+ATG 2
BU+FLU+ATG 1
FLAMSA 2
HSCT hematopoietic stem cell transplantation, AML acute myeloid leukemia,
ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, SAA severe
aplastic anemia, HL Hodgkin’s lymphoma, OMF osteomyelofibrosis, MDS
myelodysplastic syndrome, CY cyclophosphamide, BU busulphan, TBI total
body irradiation, FLU fludarabine, ATG antithymocyte globulin, MEL melphalan,
BCNU carmustine, VP-16 etoposide, ARAC cytosine arabinoside, FLAMSA
fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by
idarubicin, ANT anthracyclines
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were measured immediately by electrochemilumines-
cence immunoassay on Elecsys 2010 analyzer (Roche
Diagnostics). The upper reference limit (99th percentil)
for hs-cTnT was 0.014 μg/L and cut-off values for NT-
proBNP excluding acute heart failure were 450 and 900
pg/mL for ages < 50 and 50-75 years [8,9].
Echocardiography was performed before the condi-
tioning regimen and 1 month after HSCT. Parameters
of systolic and diastolic left ventricular (LV) function
were evaluated. Systolic LV dysfunction was defined as
ejection fraction (EF) less than or equal to 50%. To eval-
uate LV diastolic function, the following parameters
were recorded: peak flow velocity of early filling (E),
peak flow velocity of late filling (A), ratio of peak early
to peak late flow velocities (E/A), E-wave deceleration
time (DT) and isovolumetric relaxation time (IVRT).
Diastolic LV dysfunction was defined as E/A inversion
and DT above 220 ms on the transmitral Doppler curve
(impaired relaxation).
Statistical analysis
Continuous variables (echocardiographic parameters) are
presented as mean ± SD (standard deviation) and car-
diac biomarkers (NT-proBNP, hs-cTnT) as median and
interquartile range. Comparisons between continuous or
categorical variables were performed using the Student’s
t-test, Mann-Whitney and Wilcoxon test. Friedman test
was used to test the difference between variables. Corre-
lations were evaluated with Spearman correlation coeffi-
cient. A P-value less than 0,05 was considered
statistically significant.
Results
The changes in plasma NT-proBNP level during the 30
days following the HSCT were statistically significant (P
< 0,01). The highest values were detected on day 1 after
HSCT in 26 (70,3%) patients with a gradual decline, but
without normalization to baseline (Figure 1). Fourteen
days after HSCT, concentrations of NT-proBNP
remained elevated in 23 of 37 (62,2%) patients and 30
days after HSCT in 11 of 37 (29,7%) patients. In patients
who were previously treated with ANT, the NT-proBNP
level in all measurements was significantly higher com-
p a r e dt ot h o s ew h ow e r en o tt r e a t e dw i t hA N T( P =
0,01). There were no differences between patients with
or without TBI as a part of conditioning regimen (P =
0,48). Levels of NT-proBNP showed no correlation with
fever in the last week (r = 0,06; P = 0,4), with plasma
creatinine level (r = 0,03; P = 0,7) and arterial hyperten-
sion (r = 0,02; P = 0,77).
The differences in plasma hs-cTnT level during the 30
days following HSCT were also statistically significant
(Figure 2, P < 0,01). We found persistent elevations in
hs-cTnT levels 1 day, 14 days and also 30 days after
HSCT (27% vs 29,7% vs 29,7% patients). The concentra-
tions of hs-cTnT in all measurements were significantly
higher in patients previously treated with ANT (P <
0,01), but not in patients receiving TBI as a part of the
conditioning regimen (P = 0,14). Levels of hs-cTnT
showed no correlation with fever in the last week (r =
0,02; P = 0,75), with plasma creatinine level (r =- 0 , 0 2 ;
P = 0,74) and arterial hypertension (r = -0,02; P = 0,78).
Levels of NT-proBNP showed positive correlation with
hs-cTnT (r = 0,35; P < 0,01).
In the early period after HSCT, we found a statistically
significant decrease in systolic LV function (65 ± 5,7% at
baseline, 61 ± 4,8% at 1 month; P <0 , 0 1 ) .T h em e a nE /
A ratio decreased significantly over time, whereas DT
and IVRT remained unchanged (Table 2). Newly devel-
oped systolic dysfunction appeared in 5 (13,5%) patients
and diastolic dysfunction in 2 (5,4%) patients. There
were no differences in systolic echocardiographic para-
metres in patients previously treated with or without
ANT and with or without TBI as a part of the condi-
tioning regimen (P = 0,78 vs 0,27). Levels of NT-
proBNP showed negative correlation with LV EF (r =
-0,35, P = 0,03).
Of 37 patients, 5 (13,5%) developed a cardiac event.
All of these patients exhibited elevated plasma NT-
proBNP and hs-cTnT levels prior to clinical signs occur-
ing and these elevations persisted at least 30 days after
HSCT. Characteristics of patients are described in Table
3. In two patients, the cardiotoxicity was severe and
resulting in death (one patient was diagnosed with peri-
carditis and another heart failure).
Discussion
The results of this prospective and single-center study
revealed, that persistently elevated cardiac biomarkers
have important implications for identifying high-risk
patients, particularly if levels of cardiac troponins and
natriuretic peptides are simultaneously elevated for a
period exceeding 14 days. We found that NT-proBNP
and hs-cTnT might be a useful diagnostic tool for early
detection of cardiotoxicity before its clinical manifesta-
tion. All patients with clinical cardiotoxicity had con-
temporary elevations in both cardiac biomarkers before
clinical signs developed.
Natriuretic peptides elevations have been shown to
reflect wall stress, and thus provide functional informa-
tion. Although the usefulness of NT-proBNP is well
known in detection of chemotherapy-induced cardio-
toxicity, only a few reports have assessed the detection
of cardiotoxicity using BNP/NT-proBNP after allo-
geneic HSCT [10-13] or after high dose cyclophospha-
mide [14]. We found a significant rise in the plasma
NT-proBNP level one day after HSCT. This initial
Roziakova et al. Journal of Experimental & Clinical Cancer Research 2012, 31:13
http://www.jeccr.com/content/31/1/13
Page 3 of 6
Figure 1 The changes in plasma NT-proBNP level during HSCT. The changes in plasma NT-proBNP level over the 30 days following the
HSCT were statistically significant (P < 0,01). The highest values were detected on day 1 after HSCT in 26 (70,3%) patients with a gradual decline,
but without normalization to baseline. Thirty days after HSCT, NT-proBNP remained elevated in 11 of 37 (29,7%) patients.
Figure 2 The changes in plasma hs-cTnT level during HSCT. The differences in plasma hs-cTnT level over the 30 days following HSCT were
statistically significant (P < 0,01). Persistent elevations in hs-cTnT levels 1 day and also 30 days after HSCT were found in 27% vs 29,7% patients.
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of myocardial dysfunction caused by the conditioning
regimen (TBI and/or chemotherapy), or previous ANT.
It has been reported that a conditioning regimen
causes an activation of endothelial cells and macro-
phages releasing inflammatory cytokines such as tumor
necrosis factor alpha (TNF-a) or interleukins (IL) 1
and 6. There is increasing evidence that inflammatory
cytokines may also play an important role in the
pathogenesis of heart failure by inhibiting cardiac con-
tractility, promoting myocardial hypertrophy and indu-
cing cardiomyocyte apoptosis [15,16]. Elevated levels of
NT-proBNP were found in 62,2% of patients even 14
days after HSCT. The same abnormalities were also
found by Niwa et al (2002). Persistent elevations of
NT-proBNP concentrations 30 days after HSCT were
observed in 29,7% of patients, which might reflect sub-
clinical cardiotoxicity.
Cardiac troponins have been defined as the biomar-
kers potentially useful for assessing minimal myocyte
damage or loss of cell membrane integrity, and thus
give structural information. The recently introduced
highly sensitive troponin tests will expand the diagnos-
tic potential to the detection of minor injuries of the
heart and also higher cTnT levels, below the detection
r a n g eo fc u r r e n t l ya v a i l a b l ea s s a y sm a yb ec o n s i d e r e d
as a marker of “end organ” cardiovascular damage
[17,18]. For cardiotoxicity of anticancer drugs are typi-
cal low levels of cTnT. The majorities of these tropo-
nins are bound to actin and are released slowly. This
characteristic, along with the slow clearance of tropo-
nins from the body permits the detection of not only
acute damage but also of ongoing injury [19]. Baseline
plasma hs-cTnT levels were elevated in 5 (13,5%)
patients which might be associated with previous
anthracycline exposure. Persistent low-level elevations
at least 30 days after HSCT have been observed in our
study in almost one third of patients, suggesting pro-
longed effects of chemotherapy or radiotherapy on the
myofibrillar system of cardiomyocytes. Only some
authors have demonstrated the role of cardiac tropo-
nins in detection of cardiotoxicity after allogeneic
HSCT [13,20-22]. In fact, several studies have already
shown continuous damage of chemotherapy or radio-
therapy to the cardiac myofibrillar system [23-25]. In
our study, levels of NT-proBNP showed positive corre-
lation with hs-cTnT, which might indicate a relation-
ship between the degree of structural myocyte damage
and functional myocardial impairment. These observa-
tions were underscored by the echocardiographic stu-
dies which did reveal significant changes in systolic
and diastolic parameters.
Conclusions
Persistent elevations in cardiac biomarkers may reflect
the presence of an underlying reduced functional myo-
cardial reserve or reduced cardiac tolerance to cardiac
stressors. Serial measurements of plasma NT-proBNP
and hs-cTnT concentrations might be a useful tool for
identification of patients atr i s ko fd e v e l o p i n gc a r d i o -
toxicity after allogeneic HSCT and requiring cardiologi-
cal follow up. Further studies are needed to clarify
whether combination of both biomarkers improve detec-
tion of cardiotoxicity. Continued follow up is required
to bring more insight into the predictive value of these
biomarkers.
Table 2 Echocardiographic parameters before and after
HSCT
Before HSCT After HSCT P-value
Systolic parameters
LVEF (%) 65 ± 5,7 61 ± 4,8 < 0,01
Diastolic parameters
E/A 1,37 ± 0,22 1,07 ± 0,3 < 0,01
DT (ms) 174 ± 20,9 182 ± 24,5 0,3
IVRT (ms) 75,06 ± 7,5 79,11 ± 6,8 0,1
LVEF left ventricular ejection fraction, A peak flow velocity of late filling, DT E-
wave deceleration time, E peak flow velocity of early filling, IVRT isovolumetric
relaxation time
Table 3 Characteristics of patients with clinical cardiotoxicity
Patient Clinical manifestation of
cardiotoxicity
Day after
HSCT
Baseline NT-proBNP/hs-
cTnT
NT-proBNP/hs-
cTnT
Conditioning
regimen
CD ANT (mg/
m
2)
1 Chest pain, dyspnea 3 237/normal 9589/0,032 TBI + CY 390
2 Chest pain, dyspnea 1 320/normal 12 156/0,076 FLAMSA 125
3 Fluid retention, pericarditis 15 327/normal 3761/0,016 TBI + CY 150
4 Fluid retention 10 412/0,025 4817/
0,047
BUCY2 470
5 Cardiogenic shock 176 63,88/0,018 31 444/0,05 TBI + CY 150
ANT anthracyclines, CY cyclophosphamide, hs-cTnT high sensitive cardiac troponin T, NT-proBNP N-terminal pro-B-type natriuretic peptide, TBI total body
irradiation, CD cumulative dose, FLAMSA fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by idarubicin, BU busulphan
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